Article
Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis.
Frontiers in immunology - 1 Jan 2019
Kemps Paul G, Zondag Timo C, Steenwijk Eline C, Andriessen Quirine, Borst Jelske, Vloemans Sandra, Roelen Dave L, Voortman Lenard M, Verdijk Robert M, van Noesel Carel J M, Cleven Arjen H G, Hawkins Cynthia, Lang Veronica, de Ru Arnoud H, Janssen George M C, Haasnoot Geert W, Franken Kees L M C, van Eijk Ronald, Solleveld-Westerink Nienke, van Wezel Tom, Egeler R Maarten, Beishuizen Auke, van Laar Jan A M, Abla Oussama, van den Bos Cor, van Veelen Peter A, van Halteren Astrid G S
Abstract excerpt
Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder of hematopoietic origin characterized by inflammatory lesions containing clonal histiocytes (LCH-cells) intermixed with various immune cells, including T cells. In 50-60% of LCH-patients, the somatic BRAFV600E driver mutation, which is common in many cancers, is detected in these LCH-cells in an otherwise quiet genomic landscape. Non-synonymous...
Topics
- Adult
- Antigens, Neoplasm
- CD8-Positive T-Lymphocytes
- Cell Line, Tumor
- Child
- Female
- HLA-A Antigens
- Histiocytosis, Langerhans-Cell